The U.S. Food and Drug Administration said on Tuesday, the experimental vaccine from Moderna is 94.1% effective in preventing symptomatic COVID-19, FDA reports. The vaccine was found effective across racial and ethnic groups, including those with underlying medical conditions.
- The FDA report paves the way for a second shot getting emergency authorization amid rising coronavirus cases.
- FDA agency advisers will vote on Thursday on whether to recommend authorization ahead of FDA’s final decision
- FDA found Moderna vaccine 86.4% effective in people of 65 years and above and 95.6% effective for those between 18 and 65 years
- The vaccine was found to have systemic side effects of headache and fatigue.
- Moderna’s vaccine is not yet approved in any other country and hasn’t yet been used on anyone outside of a clinical trial.
- There is inadequate data to show if Moderna’s shot effectively prevents people from being infected with the coronavirus and not show symptoms.
Moderna stock is currently declining. MRNA: NASDAQ is down 2.87%
